Unrelated donor bone marrow transplantation for 100 pediatric patients: A single institute's experience

Bone Marrow Transplantation

Volumn 36, Issue 4, 2005, Pages 307-313

  Yumura Yagi, K ^a,b   Inoue, M ^b   Sakata, N ^b   Okamura, T ^b   Yasui, M ^b   Sawada, A ^b   Sato, E ^b   Chayama, K ^c   Endo, C ^c   Sasabe, M ^c   Miyamura, T ^c   Park, Y D ^d   Nakano, T ^d,h   Inagaki, J ^d   Kishimoto, T ^d   Nomura, K ^e   Saito, I ^f   Hamada, S ^g   Hashii, Y ⁱ   Kawa, K ^b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b Osaka Medical College   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^d NARA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

^f NATIONAL CANCER CENTER   (Japan)

^g UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

^h KANSAI MEDICAL UNIVERSITY   (Japan)

ⁱ OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Children; Tacrolimus; Unrelated bone marrow transplantation

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; TACROLIMUS; THIOTEPA;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CHILDHOOD DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INFANT; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; ORGAN DONOR; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; UNRELATED DONOR BONE MARROW TRANSPLANTATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HUMANS; INFANT; JAPAN; MALE; METHOTREXATE; METHYLPREDNISOLONE; PREMEDICATION; RETROSPECTIVE STUDIES; TACROLIMUS; TISSUE DONORS;

EID: 23944462929     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705056     Document Type: Article

References (19)

1. Sasazuki T, Juji T, Morishima Y et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Eng J Med 1998; 339: 1177-1185.
2. Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immuno-suppressive effect of FK506 in vitro. J Antibiot 1987; 40: 1256-1265.
3. Hamazaki T, Yagi K, Inoue M et al. Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors. Jpn J Clin Hematol 2000; 41: 430-436.
4. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
5. Dini G, Cancedda R, Giolgiani G et al. Unrelated donor marrow transplantation in children: a report from the Associazione Itariana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Traplanto Midollo Osseo (GITMO). Hematologica 2002; 87: 51-57.
6. Bunin N, Carston M, Wall D et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 2002; 99: 3151-3157.
7. Kojima S, Matsuyama T, Kato S et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002; 100: 799-803.
8. Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206.
9. Masaoka T, Shibata H, Kakishita A et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. Transplant Proc 1991; 23: 3228-3231.
10. Ratanatharathorm V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK 506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
11. Przepiorka WM, Ippoliti D, Warkentin D et al. Toxicities of tacrolimus and cyclosporine A after allogeneic blood stem cell transplantation. Bone Marrow Transplant 1997; 20: 1095-1098.
12. Sarkodee-Adoo C, Sctirescu D, Senenbrenner L et al. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transplantation 2003; 43: 78-84.
13. Oliverlo PJ, Restrepo L, Mitchell SA et al. Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. Am J Neuroradiol 2000; 21: 1251-1254.
14. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-4389.
15. Antin JH, Kim HT, Cutler C et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601-1605.
16. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant diseases. Blood 1998; 91: 756-763.
17. Toro GD, Satwani P, Harrison L et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613-622.
18. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity hemopoietic stem-cell transplantation for treatment of non-malignant disease in children. Lancet 2004; 364: 156-162.
19. Hongeng S, Krance RA, Bowman LC et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia. Lancet 1997; 350: 767-771.